Boston Scientific Co. (NYSE:BSX) Shares Sold by TD Private Client Wealth LLC

TD Private Client Wealth LLC reduced its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 23.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,207 shares of the medical equipment provider's stock after selling 11,791 shares during the quarter. TD Private Client Wealth LLC's holdings in Boston Scientific were worth $3,502,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. TFC Financial Management Inc. boosted its position in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 210 shares during the period. Global Wealth Strategies & Associates lifted its stake in shares of Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 250 shares in the last quarter. West Oak Capital LLC purchased a new stake in shares of Boston Scientific in the fourth quarter worth about $29,000. Dunhill Financial LLC grew its stake in shares of Boston Scientific by 86.4% in the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 152 shares in the last quarter. Finally, Valley National Advisers Inc. raised its holdings in shares of Boston Scientific by 262.4% during the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 286 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Remove Ads

Insider Buying and Selling at Boston Scientific

In other news, EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the transaction, the executive vice president now owns 25,443 shares of the company's stock, valued at approximately $2,704,845.33. This represents a 4.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of Boston Scientific stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the sale, the executive vice president now owns 28,454 shares in the company, valued at approximately $2,966,329.50. This represents a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 137,302 shares of company stock valued at $14,319,269 in the last ninety days. Company insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

BSX traded down $0.77 on Wednesday, hitting $102.31. 6,645,668 shares of the company's stock were exchanged, compared to its average volume of 5,794,574. The firm has a market cap of $151.32 billion, a PE ratio of 81.85, a P/E/G ratio of 2.79 and a beta of 0.77. The stock has a fifty day moving average of $101.99 and a two-hundred day moving average of $92.80. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a twelve month low of $66.80 and a twelve month high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. On average, research analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on BSX. Piper Sandler upped their price target on Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Truist Financial upped their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. StockNews.com downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th. Barclays upped their price objective on shares of Boston Scientific from $111.00 to $118.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Finally, Deutsche Bank Aktiengesellschaft raised Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research report on Friday, January 10th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.